We have previously reported that human total body clearance (CL) and steady-state volume of distribution (Vss) of monoclonal antibodies (mAbs) could be predicted reasonably well from monkey data alone using simple allometry with scaling exponents of 0.79 and 1.12 (for soluble targets), and 0.96 and 1.00 (for membrane-bound targets). In the present study, to predict the plasma concentration-time profiles of mAbs in humans, we employed simple dose-normalization and species-invariant time methods (elementary Dedrick plot and complex Dedrick plot), based on the monkey data and the scaling exponents we previously determined. The results demonstrated that the species-invariant time methods were able to provide higher accuracy of prediction than simple dose-normalization, regardless of the type of target antigens (soluble or membrane-bound). The accuracy between elementary Dedrick plot and complex Dedrick plot was nearly equivalent. The predicted human CL and Vss using species-invariant time methods were within mostly 2-fold differences from the observed values. The prediction not only of pharmacokinetic (PK) parameters but also of the plasma concentration-time profile in humans can serve as guidelines for better planning of clinical studies on mAbs.
Introduction
In our previous work, we demonstrated that the human total body clearance ¤CL¥ and steady-state volume of distribution ¤Vss¥ of monoclonal antibodies ¤mAbs¥ could be predicted reasonably well only from monkey data by using simple allometry with exponents of 0.79 and 1.12 ¤for soluble targets¥, and 0.96 and 1.00 ¤for membrane-bound targets¥. 1¥ In addition to predicting human pharmacokinetic ¤PK¥ parameters, prediction of the human plasma concentration-time profile of a drug candidate is also important during drug development, especially prior to the first-inhuman studies in terms of prediction of PK/pharmacodynamic ¤PD¥ response, estimation of efficacious doses, and dosing regimens, because efficacy and/or toxicity are generally correlated with the exposure.
Thus far, other groups reported that the human plasma concentration-time profiles of mAbs could be predicted using a species-invariant time method ¤elementary Dedrick plot¥ based on monkey data and the scaling exponents for CL ¤0.85 or 0.90¥.
2,3¥ However, those conclusions were based on the analysis of only several compounds, and most of them were the mAbs under development. Furthermore, they have not investigated which prediction method was the most appropriate one. Therefore, in the present study, in order to predict the human plasma concentration-time profiles of mAbs with more reliable accuracy, we collected more PK data for mAbs, all of which are on the market and have already verified their mechanism of action, efficacy, and pharmacokinetic disposition in clinical settings. Furthermore, we investigated which method was able to provide the highest accuracy of prediction using simple dose-normalization and species-invariant time methods ¤elementary Dedrick plot and complex Dedrick plot¥. In addition, the scaling exponents reported by other groups 2,3¥ were used for prediction to evaluate the validity of our exponents and prediction method.
Materials and Methods
Data collection: The PK data within linear range of 12 mAbs ¤6 mAbs each for soluble targets and membranebound targets¥ in monkeys and humans were obtained from the literature and from the website of the PMDA ¤Pharmaceuticals and Medical Devices Agency, Japan¥. To exclude the possibility of difference in bioavailability between species, the data after intravenous administration were collected. To the data set in our previous report for determination of the scaling exponents, 1¥ the data for belimumab, etanercept ¤iv¥, omalizumab ¤iv¥, and palivizumab ¤iv¥ were newly added to match the number of compounds between the types of target antigens ¤soluble and membrane-bound¥.
Prediction of human plasma concentration-time profiles of mAbs using simple dose-normalization and species-invariant time methods based on monkey data: The human plasma concentration-time profiles of mAbs after intravenous administration were transformed from the monkey data within linear range, using simple dose-normalization and species-invariant time methods ¤elementary Dedrick plot and complex Dedrick plot¥ described by the following equations: where BW is the body weight in kg, the dose is in mg, and e and e$ are the scaling exponents for CL and Vss, respectively. Typical body weights ¤70 kg ¤human¥, 3.75 kg ¤cynomolgus monkey¥, 6kg ¤rhesus monkey¥, 40kg ¤chimpanzee¥¥ were used. For the simple dose-normalization, e and e$ were set to be both 1.00 ¤i.e., dosenormalized PK profiles in monkeys were assumed to be equal to those in humans¥. For the elementary Dedrick plot, e and e$ were set to be 0.79 and 1.00 ¤soluble target¥ and 0.96 and 1.00 ¤membrane-bound target¥, respectively.
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For the complex Dedrick plot, e and e$ were set to be 0.79 and 1.12 ¤soluble target¥ and 0.96 and 1.00 ¤membrane-bound target¥, respectively. 1¥ The human plasma concentration-time profiles of mAbs transformed from the monkey data were fitted to the two-compartment model using the program WinNonlin ¤Model 7, version 5.2.1, Pharsight Corporation, Mountain View, CA, USA¥ to estimate the PK parameters, which served as input for the prediction of plasma concentrations in humans. The observed and predicted PK profiles of mAbs in humans were analyzed by the non-compartment model ¤WinNonlin¥, and the CL and Vss were calculated.
The exponents for CL reported by Ling et al. ¤0.85 for soluble target and 0.90 for membrane-bound target¥ 2¥ and Deng et al. ¤0.85 for both soluble and membrane-bound targets¥ 3¥ were used for prediction. In this case, the exponent for Vss was set to be 1.00, as their empirical value.
Results and Discussion
We have previously reported that the CL and Vss of mAbs in humans were able to be predicted reasonably well from monkey data using simple allometry with the scaling exponents. 1¥ The purpose of this study was to predict the plasma concentration-time profiles of mAbs in humans. So far, other groups reported that the human PK profiles of mAbs could be predicted using the elementary Dedrick plot of monkey data with a scaling exponent.
2,3¥ However, those conclusions were derived from the analyses of only a few mAbs on the market and without any investigations on the selection of prediction method. Therefore, in the present study, we collected more PK data for mAbs already used on the market and further investigated which prediction method worked best using simple dose-normalization and species-invariant time methods ¤elementary Dedrick plot and complex Dedrick plot¥.
The predicted human PK profiles over time of mAbs after intravenous administration by using simple dose-normalization and species-invariant time methods based on the monkey data are shown in Figures 1 ¤soluble target¥ and 2 ¤membrane-bound target¥. The scaling exponents we previously determined 1¥ and the PK data within linear range were used for prediction. For the mAbs targeting membrane-bound antigens, the PK profiles predicted by the elementary Dedrick plot and complex Dedrick plot were superimposed, because the scaling exponents for both methods were the same values ¤0.96 ¤for CL¥ and 1.00 ¤for Vss¥¥.
The prediction accuracy of each method was evaluated by the ratio of mAbs which met criteria, whether all of the observed concentration values were within 2-or 3-fold differences from the predicted values or not. As shown in Table 1 , the species-invariant time methods provided higher accuracy of prediction than simple dose-normalization, regardless of the type of target antigens ¤soluble or membrane-bound¥. As for etanercept, the data only up to 72 hours after a single intravenous administration to monkeys were available. Considering that a typical t 1/2 of mAb ranges from several days to a few weeks, it was too short a time to evaluate the terminal phase of elimination accurately. For the above reason, the predicted human PK profile of etanercept in the terminal phase was thought to be separated from the observed values ¤Fig. 1¥. However, even under such conditions, the prediction accuracy was within 3-fold by using the species-invariant time methods and better than for simple dose-normalization ¤Table 1¥. Although the accuracy of the complex Dedrick plot was somewhat better than the elementary Dedrick plot ¤e.g., in the case of bevacizumab at the initial phase ¤Fig. 1¥¥, they were nearly equivalent. This was because the exponents for Vss were close to 1.00 ¤1.12 for soluble target and 1.00 for membrane-bound target¥. The predicted human CL and Vss by using species-invariant time methods were compared with the observed PK parameters ¤Table 2¥. The human PK parameters could be predicted within mostly 2-fold differences from the observed values for both types of target antigens.
In order to evaluate the validity of our exponents and prediction method, we also simulated the human PK profiles The concentration-time profiles of mAbs in humans were transformed from the monkey data using simple dose-normalization and speciesinvariant time methods (elementary Dedrick plot and complex Dedrick plot). The concentration axis was normalized by dose ((µg/mL)/(mg/kg)). Closed circle, observed value; bold solid line, predicted value; dashed line, 2-fold difference from the predicted value; bold dashed line, 3-fold difference from the predicted value.
using the CL exponents reported by other groups ¤0.85 or 0.90¥ 2,3¥ and compared the prediction accuracy with our results in the same way ¤Table 3 ¤the detailed PK profiles are available as an online supplement¥. In this case, the exponent for Vss was set to be 1.00 as their empirical value, whereby the PK profiles predicted by the elementary Dedrick plot and complex Dedrick plot were superimposed. The reported exponents by other groups also provided reasonably good accuracy for the prediction; however, the accuracy by our exponents looked slightly better in some The concentration-time profiles of mAbs in humans were transformed from the monkey data using simple dose-normalization and speciesinvariant time methods (elementary Dedrick plot and complex Dedrick plot). The concentration axis was normalized by dose ((µg/mL)/(mg/kg)). The predicted PK profiles by the elementary Dedrick plot and complex Dedrick plot were superimposed, because the scaling exponents for both methods had the same values. Closed circle, observed value; bold solid line, predicted value; dashed line, 2-fold difference from the predicted value; bold dashed line, 3-fold difference from the predicted value.
cases ¤e.g., bevacizumab ¤initial phase¥ and tocilizumab ¤terminal phase¥¥.
In summary, we expanded on the previous works by us and others, and demonstrated that the species-invariant time methods based on monkey data could predict the human PK profiles of mAbs within mostly 2-fold differences from the observed values. Because of similarities in many aspects between monkeys and humans ¤e.g., binding epitope, binding affinity to the target antigen, and the tissue-cross reactivity profile¥, monkeys are commonly and frequently used for When all of the observed values were within 2-or 3-fold differences from the predicted values, these were denoted by úYes.û For the mAbs targeting membrane-bound antigens ¤exponent for Vss: 1.00¥, the predicted PK profiles for the complex Dedrick plot were superimposed with those for the elementary Dedrick plot, resulting in the prediction accuracy between them being the same. Antibodies with prediction accuracy within 2-fold ¤%¥ 83 83 Antibodies with prediction accuracy within 3-fold ¤%¥ 100 100
The observed and predicted PK profiles were analyzed by a non-compartment model.
PK and toxicological studies of mAbs. Therefore, this method is useful and can serve as a guideline for better planning of clinical studies on mAbs.
